Bionano Genomics, Inc.

BNGO Healthcare Medical Instruments & Supplies

Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024.

Revenue
+21.4%
EPS
+67.8%
Free cash flow
−33.9%
Total debt
−1.91%

Quarter to June 2026, against a year earlier

1.11 0.08 −6.72%
Market cap
$15.4M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
5/9
Altman Z
−14.26
Beneish M
−3.39
Dividend safety
n/a

Bionano Genomics, Inc. (BNGO) P/E ratio

Alert me on P/E ratio

Bionano Genomics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
31 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
FEMY Femasys Inc. compare n/m
LUCY Innovative Eyewear, Inc. compare n/m
MLSS Milestone Scientific, Inc. compare n/m
NXGL NexGel, Inc. compare n/m
BNGO Bionano Genomics, Inc. n/m
RVP Retractable Technologies, Inc. compare n/m
NEPH Nephros Inc. compare 18.0×
RGNT Regentis Biomaterials Ltd. compare —
CUPR Cuprina Holdings (Cayman) Limited compare —
Medical Instruments & Supplies industry median 30.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BNGO